DNB Markets 5 th Annual Health Care Conference, 11 December 2014 CEO Luigi Costa

Size: px
Start display at page:

Download "DNB Markets 5 th Annual Health Care Conference, 11 December 2014 CEO Luigi Costa"

Transcription

1 DNB Markets 5 th Annual Health Care Conference, December 0 CEO Luigi Costa Nordic Nanovector ASA Kjelsåsveien 68 B, 088 Oslo, Norway -

2 Forward-looking statements This presentation has been prepared by representatives of Nordic Nanovector ASA (the Company ) for use in presentations by the Company solely for information purposes, and this document and the information contained herein may not be disclosed, taken away, reproduced, redistributed, copied or passed on, directly or indirectly, to any other person or published or used in whole or in part, for any purpose. This presentation does not constitute a recommendation regarding any securities of the Company. No representation, warranty, or undertaking, express or implied, is made by the Company or its or representatives as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein, for any purpose whatsoever. Neither the Company nor any of its representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. All information in this presentation is subject to updating, revision, verification, correction, completion, amendment and may change materially and without notice. In giving this presentation, the Company and its representatives do not undertake any obligation to provide the recipient with access to any additional information or to update this presentation or any information or to correct any inaccuracies in any such information. The information contained in this presentation should be considered in the context of the circumstances prevailing at the time and has not been, and will not be, updated to reflect material developments which may occur after the date of the presentation. Matters discussed in this document and any materials distributed in connection with this presentation may constitute or include forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as believes, expects, anticipates, intends, estimates, will, may, continues, should and similar expressions. These forward-looking statements reflect the Company s beliefs, intentions and current expectations concerning, among other things, the Company s research & development achievements and testing results, product development, results of operations, financial condition, liquidity, prospects, growth and strategies. Forward-looking statements include statements regarding: objectives, goals, strategies, outlook and growth prospects; future plans, events or performance and potential for future growth; and liquidity, capital resources and capital expenditures. Forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. The forward-looking statements in this presentation are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Forward-looking statements are not guarantees of future performance and such risks, uncertainties, contingencies and other important factors could cause the actual results of operations, financial condition and liquidity of the Company or the industry to differ materially from those results expressed or implied in this presentation by such forward-looking statements. No representation is made that any of these forward-looking statements or forecasts will come to pass or that any forecast result will be achieved and you are cautioned not to place any undue influence on any forward-looking statement. This document and the information contained herein does not constitute or form a part of, and should not be construed as, an offer for sale or subscription of or solicitation or invitation of any offer to subscribe for or purchase any securities of the Company and neither this document nor anything contained herein shall form the basis of, or be relied on in connection with, any offer or commitment whatsoever. This presentation and the information contained herein are not an offer of securities for sale in the United States and are not for publication or distribution to persons in the United States (within the meaning of Regulations under the U.S. Securities Act of 9, as amended (the Securities Act )). The securities of the Company have not been and will not be registered under the Securities Act and may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. Any failure to comply with this restriction may constitute a violation of United States securities laws. Neither this document nor any copy of it may be taken, released, published, transmitted or distributed, directly or indirectly, in or into the United States, Canada, Australia or Japan. Any failure to comply with this restriction may constitute a violation of United States, Canadian, Australian or Japanese securities laws. This document is also not for publication, release or distribution in any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction nor should it be taken or transmitted into such jurisdiction and persons into whose possession this document comes should inform themselves about and observe any such relevant laws. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will not be accepted.

3 Agenda 5 6 Company in brief Our lead product candidate, Betalutin Market highlights Status on Betalutin clinical development Financial highlights Key take-aways

4 Nordic Nanovector: the North Star for innovative cancer treatment Our mission Nordic Nanovector is an innovation-driven biotech company that discovers, manufacturers and delivers to patients innovative, cost-effective, targeted radioimmunotherapy (RIT) clinical solutions to address major unmet medical needs and advance cancer care Facts and figures Nordic Nanovector was established in 009 by Roy Larsen and Inven Promising leading product candidate, Betalutin, a RIT clinical solution, for the treatment of non-hodgkin lymphoma (moving into phase II) Management team with broad industry experience from international pharmaceutical and biotech companies Committed to developing a promising pipeline with strong focus on hematology Favorable financial position with MNOK 9 in cash by Q 0 and strong investor base

5 Betalutin, first of a new generation of RIT clinical solutions for immunological malignancies Betalutin - the first of a new generation of RIT: Strong IP and unique patented technology Tumor seeking monoclonal antibody (HH*), targeting CD7 antigens on lymphoma cells Conjugated radionuclide (Lutetium-77) Innovative mechanism of action: targeted approach with systemic effect (multi-cell kill) Betalutin is currently moving into Phase II clinical development *Developed by the Norwegian Radium Hospital 5

6 Current therapies, including Rituximab and Immuno- Conjugates, have certain limits The antibodies seek out their antigen targets on the surface of individual cancer cells to elicit a response through cancer cell death However, tumor biology and tumor cell transformation make single cell kill of all tumor cells very difficult to achieve 6

7 Betalutin uses a multi-cell kill approach, but it is different from currently marketed RIT HH targets a unique antigen (CD7) allowing broader and more sustained clinical response even when CD0 targeted therapies are no longer effective It emits low energy beta particles with shorter penetration that affect even surrounding transformed tumor cells It has a biological half-life which allows optimized delivery of radiation to tumor cells It can be used for direct imagining and dosimetry Betalutin can be used synergistically with CD0 targeted therapies 7

8 # of patients in 6 major markets Billion USD NHL is a life-threatening blood cancer, with a highly unmet medical need NHL (non-hodgkin lymphoma) is the 0 th most common cancer, with a high mortality rate Incidence is expected to grow, CAGR.5% The market has the potential for significant growth (CAGR 7%, until 08) Expected increasing incidence NHL market expected to reach ~ USD bn by Spain Italy UK France Germany US f 07f 09f 0f Source: EUCAN 0 (http://eco.iarc.fr/eucan); SEER (http://seer.cancer.gov/statistics/); LSC analysis Global Non-Hodgkin Lymphoma Therapeutics Market : 0-08 (TechNavio) APAC EMEA Americas 8

9 Phase I Study of 77 lu-dota-hh (Betalutin TM ) RIT for Patients with relapsed CD7 + B-Cell NHL Abstract 09 Prof. A. Kolstad et al Patient characteristics Study design + dose escalation study dose levels tested DL: 0 MBq/kg b.w DL: 0 MBq/kg b.w DL: 5 MBq/kg b.w Study objectives Primary: Maximum tolerated dose (MTD) Secondary: Safety and toxicity Recommended phase dose Biodistribution and blood PK Tumor responses Characteristics Median age (years) Range Male Female Primary diagnosis FL MCL Number of prior treatments, range 0 MBq/kg b.w n= MBq/kg b.w n= MBq/kg b.w n= Total N= FL = Follicular Lymphoma; MCL = Mantle Cell Lymphoma 9

10 Betalutin safety profile predictable and manageable; max tolerated dose reached at 0 MBq/kg b.w. CTCAE grade and treatment related adverse events 0 ( pts) MBq/kg b.w. 0 ( pts) MBq/kg b.w. 5 ( pts) MBq/kg b.w. Total pts CTCAE grade Platelets Neutrophils Pneumonia Epistaxis * Table shows number of patients qualified for DLTs. Number of patients reported. Related adverse events = possible or probable DLT by dose level DL Enrolled DLTs MBq/kg b.w. n n Details Grade thrombocytopenia Grade thrombocytopenia CTCAE = Common Terminology Criteria for Adverse Events DLT = Dose limiting toxicity 0

11 Betalutin achieved a 6% overall response rate (ORR) with 6% complete response (CR) rate Best tumor response by dose level Response 0 MBq/kg b.w n= 0 MBq/kg b.w n= 5 MBq/kg b.w n= Total n= Complete response (CR) Partial response (PR) Stable disease (SD) Progressive disease (PD) Overall response (CR+PR) 7 Tumor response was assessed according to the International Working Group revised Response Criteria (Cheson 007 )

12 Betalutin TM 5MBq/kg delivers promising clinical results as confirmed by PET/CT-scan Complete metabolic response (FDG PET/CT) at 6 months in patient 008, DL 5 MBq/kg b.w., with FL

13 Adequate funding Solid cash position of NOK 9M - $8M* (OB Q) Key burn rate drivers: Acceleration in R&D activities Personnel Infrastructure Discovery Available cash should support the execution of main R&D and pre-commercialization strategy to 07 Planned IPO in 05 pending market conditions * Cash rate USD = 6.8

14 Key take-aways 5 6 Innovation-driven biotech company, aspiring to become a leader in RIT Promising product candidate in NHL (effective, safe and convenient) Ambitious, accelerated product development plan Commitment to maximise company s value through pipeline development and geographic expansion Solid financial situation with planned IPO in 05 to support key activities and maintain independence Strong team with international experience and know-how in oncohematology and nuclear medicine

15 Thank you for your attention! Nordic Nanovector ASA Kjelsåsveien 68 B, 088 Oslo, Norway

Swiss-Scandinavian Bio-Business Seminar, 10 February 2016 Zurich, Switzerland

Swiss-Scandinavian Bio-Business Seminar, 10 February 2016 Zurich, Switzerland Swiss-Scandinavian Bio-Business Seminar, 10 February 2016 Zurich, Switzerland Tone Kvåle, Chief Financial Officer Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway - www.nordicnanovector.com

More information

Localised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment

Localised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment Localised Cancer Treatment PCI Biotech Amphinex a new product for localised cancer treatment Disclaimer This document (the Presentation ) has been produced by PCI Biotech Holding ASA (the Company ). The

More information

Full Year Report 2005. 26 January 2006

Full Year Report 2005. 26 January 2006 Full Year Report 2005 26 January 2006 Important Notice This Presentation has been produced by TradeDoubler AB (the Company ) and is furnished to you solely for your information. This document contains

More information

The Stock Market Show. Parsortix non-invasive cancer diagnostics. Andrew Newland 13 September 2014

The Stock Market Show. Parsortix non-invasive cancer diagnostics. Andrew Newland 13 September 2014 The Stock Market Show Parsortix non-invasive cancer diagnostics Andrew Newland 13 September 2014 Legal disclaimer The information and opinions contained in this presentation are provided as at the date

More information

Update following the publication of the Bank of England Stress Test. 16 December 2014

Update following the publication of the Bank of England Stress Test. 16 December 2014 Update following the publication of the Bank of England Stress Test 16 December 2014 Background Top 8 Banks Resilience Stress Tested by PRA following FPC recommendation in March 2013 Guidance for stress

More information

Interim report Second quarter 2015

Interim report Second quarter 2015 Interim report Second quarter 2015 Oslo, 20 August 2015 Presenters and agenda Agenda Hans-Petter Mellerud Founder and CEO Highlights for the quarter Financial performance Regional trends Nina Stemshaug

More information

Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO

Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO 1 PCI BIOTECH Important notice and disclaimer This presentation may contain certain forward-looking statements and forecasts based

More information

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies

More information

Company presentation. Acquisition of Asan (Cederroth AS) and contemplated private placement. 17 December 2015

Company presentation. Acquisition of Asan (Cederroth AS) and contemplated private placement. 17 December 2015 Company presentation Acquisition of Asan (Cederroth AS) and contemplated private placement 17 December 2015 1 Disclaimer This presentation (the "Presentation") has been produced by Weifa ASA (the Company

More information

Gjensidige in brief. Attractive position in Nordic GI. Balanced retail portfolio. Private and SME exposure 80 % direct distribution

Gjensidige in brief. Attractive position in Nordic GI. Balanced retail portfolio. Private and SME exposure 80 % direct distribution 1 Gjensidige in brief Attractive position in Nordic GI Balanced retail portfolio Accident & Health 21% Motor 33% Property 36% 200 years history Earned premiums : NOK bn 19 Equity: NOK bn 26 Market cap:

More information

Gjensidige Bank. Investor Presentation Q May 2015

Gjensidige Bank. Investor Presentation Q May 2015 Gjensidige Bank Investor Presentation Q1 2015 6. May 2015 Content Gjensidige and Gjensidige Bank in brief Financial performance Funding overview Appendix Gjensidige Bank in Brief KEY FINANCIALS 1 st QUARTER

More information

FONDUL PROPRIETATEA S.A.

FONDUL PROPRIETATEA S.A. To: Bucharest Stock Exchange Financial Supervisory Authority Current report according to Article 99 of the Code of the Bucharest Stock Exchange, Title II, Issuers and Financial Instruments. Events to be

More information

NICKEL MOUNTAIN GROUP AB

NICKEL MOUNTAIN GROUP AB Company presentation NICKEL MOUNTAIN GROUP AB «Building a high growth, high return debt management services company» 16 October 2015 NOT FOR REPRODUCTION OR DISTRIBUTION. THE INFORMATION CONTAINED HEREIN

More information

Developing First-in-Class Treatments in Haematologic Cancers Biotech Showcase 2017, San Francisco, January 9 th 2017

Developing First-in-Class Treatments in Haematologic Cancers Biotech Showcase 2017, San Francisco, January 9 th 2017 Developing First-in-Class Treatments in Haematologic Cancers Biotech Showcase 2017, San Francisco, January 9 th 2017 \\AD.JEFCO.COM\BANKING\HEALTHCARE INTL\DEALS\NOR45600IB - TARGET\2. FROM COMPANY\011216

More information

April 2016. Bruno Jactel, CEO Erica Boisvert, CFO

April 2016. Bruno Jactel, CEO Erica Boisvert, CFO April 2016 Bruno Jactel, CEO Erica Boisvert, CFO OUR MISSION TYRATECH Is a life science technology company focused on: pesticide-free products to control insects and parasites 1 ton of pesticide per person/year!

More information

CAR Inc annual results presentation. March 2015

CAR Inc annual results presentation. March 2015 CAR Inc. 2014 annual results presentation March 2015 Disclaimer By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following

More information

Marel has agreed to acquire MPS meat processing systems for 382 million on a debt and cash-free basis Parallel Marel secured close to 670 million

Marel has agreed to acquire MPS meat processing systems for 382 million on a debt and cash-free basis Parallel Marel secured close to 670 million Marel has agreed to acquire MPS meat processing systems for 382 million on a debt and cash-free basis Parallel Marel secured close to 670 million senior long term financing for the group at favorable terms

More information

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION INTO OR IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN. 6 June 2007

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION INTO OR IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN. 6 June 2007 NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION INTO OR IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN 6 June 2007 Amsterdam Molecular Therapeutics announces launch of Initial Public Offering (IPO) on Euronext

More information

MOBILE EMBRACE ASX: MBE. Capital Raise June 2016 Chris Thorpe, CEO REACH ENGAGE TRANSACT EMBRACE

MOBILE EMBRACE ASX: MBE. Capital Raise June 2016 Chris Thorpe, CEO REACH ENGAGE TRANSACT EMBRACE MOBILE EMBRACE ASX: MBE Capital Raise June 2016 Chris Thorpe, CEO 1 DEAL OVERVIEW AND USE OF FUNDS We would like to welcome a number of new financial institutions to the MBE Share Register through a heavily

More information

X5 Retail Group Capital Markets Day

X5 Retail Group Capital Markets Day X5 Retail Group Capital Markets Day Presentation for Investors Janusz Lella 11 th October, 2013 General Director of Perekrestok 11 October 2013 Disclaimer This presentation does not constitute or form

More information

Market Update and Capital Raising 12 November, 2008

Market Update and Capital Raising 12 November, 2008 Market Update and Capital Raising 12 November, 2008 Dr Colin Goldschmidt CEO and Managing Director Sonic Healthcare 1 NOT FOR DISTRIBUTION IN THE UNITED STATES OR TO US PERSONS Important Notice and Disclaimer

More information

World-leading expertise in Gene and Cell Therapy

World-leading expertise in Gene and Cell Therapy Worldleading expertise in Gene and Cell Therapy Jefferies Healthcare Conference New York, June 2015 Disclaimer The information contained in this presentation is being supplied and communicated to you on

More information

B U I L D I N G N O R T H A M E R I C A N F I N T E C H L E A D E R S H I P. BMO 2013 Technology and Digital Media Conference

B U I L D I N G N O R T H A M E R I C A N F I N T E C H L E A D E R S H I P. BMO 2013 Technology and Digital Media Conference B U I L D I N G N O R T H A M E R I C A N F I N T E C H L E A D E R S H I P BMO 2013 Technology and Digital Media Conference Forward-Looking Statements This presentation contains certain statements that

More information

Telio & NextGenTel. NextGenTel Holding ASA. Q1 2015 Presentation. Eirik Lunde, CEO. Felix Konferansesenter Oslo 7 May 2015

Telio & NextGenTel. NextGenTel Holding ASA. Q1 2015 Presentation. Eirik Lunde, CEO. Felix Konferansesenter Oslo 7 May 2015 Telio & NextGenTel NextGenTel Holding ASA Q1 215 Presentation Eirik Lunde, CEO Felix Konferansesenter Oslo 7 May 215 This is NextGenTel Group Background Telio Pioneer in the Norwegian VoIP market rapid

More information

Gjensidige Insurance Group Q4 2008 and preliminary 2008

Gjensidige Insurance Group Q4 2008 and preliminary 2008 Gjensidige Insurance Group Q4 2008 and preliminary 2008 Disclaimer The information contained herein has been prepared by and is the sole responsibility of Gjensidige Forsikring BA ( the Company ). Such

More information

Welcome and objectives - Luigi Costa, CEO

Welcome and objectives - Luigi Costa, CEO Welcome and objectives - Luigi Costa, CEO Market Capital Day, November 17 th 2015 Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway - www.nordicnanovector.com 0 Forward-looking statements This

More information

ONLINE TRAFFIC MONITIZATION EXPERT. 8 February

ONLINE TRAFFIC MONITIZATION EXPERT. 8 February ONLINE TRAFFIC MONITIZATION EXPERT 8 February 2015 1 About Us Who we are? We are an online performance marketing company What we do? We attract paying users from multiple online channels and direct them

More information

Annual Financial Results Presentation for year ended 30 June 2014 2 October 2014

Annual Financial Results Presentation for year ended 30 June 2014 2 October 2014 Annual Financial Results Presentation for year ended 30 June 2014 2 October 2014 Disclaimer The information contained in this presentation ( Presentation ) has been prepared by Firestone Diamonds plc (the

More information

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck

More information

BB Healthcare Trust plc

BB Healthcare Trust plc 30 November 2016 NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY MEMBER STATE OF THE EEA

More information

Ubiquitous secure file sharing on any device

Ubiquitous secure file sharing on any device Ubiquitous secure file sharing on any device This presentation is not an offer to sell or a solicitation of an offer to purchase securities by Zyber Secure Mobile Solutions Inc. ( Zyber ). Any such offer

More information

2014 FULL YEAR RESULTS

2014 FULL YEAR RESULTS 2014 FULL YEAR RESULTS -3% -8% Financial and Operational Highlights Operational Revenue mntl (1) Ancillary Revenue/Pax Load Factor 29% 16% 13% 22% TRY mn 2.38 4,7 TRY mn 3.08 1,7 TRYm n 569,3 TRYm n 661,9

More information

Adif - Alta Velocidad

Adif - Alta Velocidad Adif - Alta Velocidad Investor Presentation January 2015 Adif - Alta Velocidad Receipt of this presentation implies your agreement with the restrictions outlined below. NOTHING IN THIS PRESENTATION CONSTITUTES

More information

Recommended Acquisition of Networkers International plc Presentation to Analysts & Investors

Recommended Acquisition of Networkers International plc Presentation to Analysts & Investors Recommended Acquisition of Networkers International plc Presentation to Analysts & Investors 28 January 2015 Disclaimer THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL SECURITIES.

More information

Design the future. Second quarter results 2015. Detlef Borghardt, CEO Wilfried Trepels, CFO. August 06, 2015

Design the future. Second quarter results 2015. Detlef Borghardt, CEO Wilfried Trepels, CFO. August 06, 2015 Design the future Second quarter results 215 Detlef Borghardt, CEO Wilfried Trepels, CFO August 6, 215 Agenda 1 Market Development 3 2 Financial information 5 3 Outlook 17 2 Truck and trailer market development

More information

Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022

Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Brochure More information from http://www.researchandmarkets.com/reports/2228475/ Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis and

More information

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019 Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive

More information

Scotiabank Financials Summit September 4, 2014

Scotiabank Financials Summit September 4, 2014 Scotiabank Financials Summit September 4, 2014 Customers Capital Bank ~7,000 customers, high level of recurring revenue 2 Forward-Looking Statements This presentation contains certain statements that constitute

More information

SBERBANK GROUP S IFRS RESULTS. March 2015

SBERBANK GROUP S IFRS RESULTS. March 2015 SBERBANK GROUP S IFRS RESULTS 2014 March 2015 SUMMARY OF PERFORMANCE FOR 2014 STATEMENT OF PROFIT OR LOSS Net profit reached RUB 290.3bn (or RUB 13.45 per ordinary share), compared to RUB 362.0bn (or RUB

More information

New Advances in Cancer Treatments. March 2015

New Advances in Cancer Treatments. March 2015 New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within

More information

Focus on fleet customers SAF-HOLLAND Annual Financial Statements 2013

Focus on fleet customers SAF-HOLLAND Annual Financial Statements 2013 Focus on fleet customers SAF-HOLLAND Annual Financial Statements 213 Detlef Borghardt, CEO Wilfried Trepels, CFO March 13, 214 Agenda 1 Financials 3 2 Appendix 21 2 Executive Summary 1 2 3 Group sales

More information

MERKO EHITUS GROUP Annual General Meeting of Shareholders. 29 April 2015 Nordic Hotel Forum, Tallinn

MERKO EHITUS GROUP Annual General Meeting of Shareholders. 29 April 2015 Nordic Hotel Forum, Tallinn MERKO EHITUS GROUP Annual General Meeting of Shareholders 29 April 2015 Nordic Hotel Forum, Tallinn Agenda 1. Approval of the annual report of the year 2014 and overview of the results and the prospective

More information

SAF-HOLLAND Annual Financial Statements 2012. Detlef Borghardt, CEO Wilfried Trepels, CFO. March 14, 2013

SAF-HOLLAND Annual Financial Statements 2012. Detlef Borghardt, CEO Wilfried Trepels, CFO. March 14, 2013 SAF-HOLLAND Annual Financial Statements 212 Detlef Borghardt, CEO Wilfried Trepels, CFO March 14, 213 Executive Summary business volume successfully expanded in 212 1 Group sales increased yoy by 3.4%

More information

Sberbank Group s IFRS Results for 6 Months 2013. August 2013

Sberbank Group s IFRS Results for 6 Months 2013. August 2013 Sberbank Group s IFRS Results for 6 Months 2013 August 2013 Summary of 6 Months 2013 performance: Income Statement Net profit reached RUB 174.5 bn (or RUB 7.95 per ordinary share), a 0.5% decrease on RUB

More information

Fourth Quarter 2014. Published February 25, 2015. www.asetek.com

Fourth Quarter 2014. Published February 25, 2015. www.asetek.com Fourth Quarter 2014 Published February 25, 2015 Disclaimer This presentation and its enclosures and appendices (jointly referred to as the Presentation ) has been produced by Asetek A/S (the Company )

More information

Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation

Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation Hans S. Keirstead President, NeoStem Oncology NeoStem Presented by GTC, a conference production company 626-256-6405

More information

BIOLIFE SOLUTIONS INC

BIOLIFE SOLUTIONS INC SECURITIES & EXCHANGE COMMISSION EDGAR FILING BIOLIFE SOLUTIONS INC Form: 8-K Date Filed: 2016-01-07 Corporate Issuer CIK: 834365 Copyright 2016, Issuer Direct Corporation. All Right Reserved. Distribution

More information

BANCA MONTE DEI PASCHI DI SIENA: BUSINESS PLAN APPROVED

BANCA MONTE DEI PASCHI DI SIENA: BUSINESS PLAN APPROVED PRESS RELEASE BANCA MONTE DEI PASCHI DI SIENA: 2013-2017 BUSINESS PLAN APPROVED The document implements the strategic and operational priorities of the Restructuring Plan submitted on 7 October 2013 and

More information

Service efficiency - Key driver for profitability improvement

Service efficiency - Key driver for profitability improvement Service efficiency - Key driver for profitability improvement Matti Malmberg, Building Services Northern Europe and Service Efficiency Capital Markets Day in Frankfurt November 19, 2013 Contents o Building

More information

Second Quarter and First Half 2015 Trading Update

Second Quarter and First Half 2015 Trading Update Second Quarter and First Half 2015 Trading Update Trading Performance Year-on-Year Gross Profit Reported ( m) Constant 2015 2014 % % Q2 145.3 137.1 +6.0% +10.6% H1 281.0 263.7 +6.6% +10.8% Q2 Gross Profit

More information

BH Macro Limited. BH Global Limited. Webcast. A FTSE 250 Company. A FTSE 250 Company

BH Macro Limited. BH Global Limited. Webcast. A FTSE 250 Company. A FTSE 250 Company BH Macro Limited A FTSE 250 Company BH Global Limited A FTSE 250 Company Bloomberg: BHMF LN, BHME LN, BHMU LN Shareholder website: www.bhmacro.com Bloomberg: BHGG LN, BHGE LN, BHGU LN Shareholder website:

More information

pressrelease ROCKET INTERNET PRICES IPO AT TOP OF PRICE RANGE MANILA, Philippines, 2 nd October 2014 - Philippine Long Distance Telephone Company ( PLDT ) (PSE:TEL) (NYSE:PHI), the leading telecoms operator

More information

CORPORATE TREASURY SERVICES. Helping to Create and Protect Capital in Changing Markets and Economic Conditions.

CORPORATE TREASURY SERVICES. Helping to Create and Protect Capital in Changing Markets and Economic Conditions. r CORPORATE TREASURY SERVICES Helping to Create and Protect Capital in Changing Markets and Economic Conditions. Set your Goals. Make them Happen. Expert Resources to Meet your Specific Needs WHAT WE DO

More information

Gjensidige Insurance Group Q2 2012

Gjensidige Insurance Group Q2 2012 Gjensidige Insurance Group Q2 2012 Agenda Highlights Financial performance Outlook and priorities Supplementary information Record-high insurance result NOK 3.00 2.50 2.00 1.50 1.00 0.50 0.00 Earnings

More information

RESULTS FIRST QUARTER 2015

RESULTS FIRST QUARTER 2015 0 April 27, 2015 RESULTS FIRST QUARTER 2015 An integrated energy player focused on exploration and production DISCLAIMER 1 RCA figures except otherwise noted. By attending or reading this presentation,

More information

Adaptimmune Reports Full Fiscal Year 2015 Financial Results. - Conference call to be held today at 8:00 AM ET (1:00 PM BST) -

Adaptimmune Reports Full Fiscal Year 2015 Financial Results. - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - Adaptimmune Reports Full Fiscal Year 2015 Financial Results - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - PHILADELPHIA, Pa. and OXFORD, United Kingdom., October 13, 2015 Adaptimmune

More information

Travelex. Helping customers to send and spend money around the world. March 2014

Travelex. Helping customers to send and spend money around the world. March 2014 Travelex Helping customers to send and spend money around the world March 2014 Notice to Recipient THE INFORMATION CONTAINED IN THIS CONFIDENTIAL DOCUMENT ( PRESENTATION ) HAS BEEN PREPARED BY TRAVELEX

More information

RUNNINGBALL ACQUISITION INVESTOR PRESENTATION

RUNNINGBALL ACQUISITION INVESTOR PRESENTATION RUNNINGBALL ACQUISITION INVESTOR PRESENTATION TRANSACTION HIGHLIGHTS Proposed acquisition of RunningBall group, a leading provider of real-time sports data to the online sports betting sector Consideration

More information

WELCOME! Introduction. Celebrating. &PrimeRevenue. PrimeRevenue Hong Kong. 2012 PrimeRevenue, Inc.

WELCOME! Introduction. Celebrating. &PrimeRevenue. PrimeRevenue Hong Kong. 2012 PrimeRevenue, Inc. WELCOME! Introduction Celebrating Ethe Factor Network establishment of &PrimeRevenue PrimeRevenue Hong Kong 2012 PrimeRevenue, Inc. Global Reach Today, we transact business in 50 countries Our platform

More information

NextGenTel Holding ASA The Kvantel acquisition. Eirik Lunde, CEO. Felix Konferansesenter Oslo, 15 October 2015

NextGenTel Holding ASA The Kvantel acquisition. Eirik Lunde, CEO. Felix Konferansesenter Oslo, 15 October 2015 NextGenTel Holding ASA The Kvantel acquisition Eirik Lunde, CEO Felix Konferansesenter Oslo, 15 October 2015 Agenda NextGenTel Growth initiatives the business segment Kvantel Company history in brief Products

More information

ANNUAL GENERAL MEETING Z A L A N D O S E. 2 J u n e 2015 T e m p o d r o m, B e r l i n

ANNUAL GENERAL MEETING Z A L A N D O S E. 2 J u n e 2015 T e m p o d r o m, B e r l i n ANNUAL GENERAL MEETING Z A L A N D O S E 2 J u n e 2015 T e m p o d r o m, B e r l i n 1 Zalando corporate video 2 WELCOME TO THE ANNUAL GENERAL MEETING 2015 T h e M a n a g e m e n t B o a r d w e l c

More information

Achmea Investment Management. 26 May 2016 Jacob de Wit Leiden

Achmea Investment Management. 26 May 2016 Jacob de Wit Leiden Achmea Investment Management 26 May 2016 Jacob de Wit Leiden Key messages Strategic choice of Achmea for Retirement Services with Achmea IM as Asset Manager Centralisation of asset management activities

More information

XXL ASA - Announcement of terms in the Initial Public Offering

XXL ASA - Announcement of terms in the Initial Public Offering NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF

More information

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015 Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future

More information

Xtract Resources Plc (AIM:XTR) Chepica Gold Mine: Quarterly Results Presentation

Xtract Resources Plc (AIM:XTR) Chepica Gold Mine: Quarterly Results Presentation Xtract Resources Plc (AIM:XTR) Chepica Gold Mine: Quarterly Results Presentation London 3 February 2016 Aerial view of Chepica Gold Mine Taken with Phantom 3 Professional Drone 2 We are xtracting significant

More information

Aphria Inc. - TSXV:APH Q1 2016 Financial Highlights & Investor Presentation January 6, 2016

Aphria Inc. - TSXV:APH Q1 2016 Financial Highlights & Investor Presentation January 6, 2016 Aphria Inc. - TSXV:APH Q1 2016 Financial Highlights & Investor Presentation January 6, 2016 DISCLAIMER This documentation is a presentation (the Presentation ) of general background information about Aphria

More information

IMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282

IMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS, INC. 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2014 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS Morris

More information

Investors Day 2007 Achievements and new targets

Investors Day 2007 Achievements and new targets Investors Day 2007 Achievements and new targets Rolf Dörig, Group CEO Zurich, 4 December 2007 Investors Day 2007: Highlights Recently announced achievements 4 September Confirmed 1 bn net profit in 2007

More information

EQUITY RAISING ANNOUNCEMENT

EQUITY RAISING ANNOUNCEMENT EQUITY RAISING ANNOUNCEMENT MARKET RELEASE 21 NOVEMBER 2012 KEY POINTS Entitlement Offer to Raise up to A$80 million o 3 for 10 accelerated non renounceable entitlement offer to raise up to A$80 million

More information

CURATING THE ASSORTMENT. Capital Markets Day 25 March 2015

CURATING THE ASSORTMENT. Capital Markets Day 25 March 2015 CURATING THE ASSORTMENT Capital Markets Day 25 March 2015 CUSTOMER EXPECTATIONS HAVE DEVELOPED SIGNIFICANTLY OVER THE LAST YEARS W O W! S H O P P I N G O N L I N E! W O W! A L L T H E P R O D U C T S I

More information

1st Quarter 2012 GE Healthcare DiaGenic collaboration: PET imaging and gene signatures

1st Quarter 2012 GE Healthcare DiaGenic collaboration: PET imaging and gene signatures 1st Quarter 2012 GE Healthcare DiaGenic collaboration: PET imaging and gene signatures Henrik Lund MD PhD, CEO Magnus Sjögren, MD PhD, CMO Ruben Ekbråten, CFO Disclaimer This document (the Presentation

More information

PREMIER OIL plc ("Premier") Result of Extraordinary General Meeting. 20th April 2009

PREMIER OIL plc (Premier) Result of Extraordinary General Meeting. 20th April 2009 Not for release, publication or distribution in or into Australia, Canada, the Dubai International Financial Centre, New Zealand, the Republic of South Africa, the State of Israel or the United States

More information

PHOTOCURE ASA BUILDING A SPECIALTY PHARMA COMPANY

PHOTOCURE ASA BUILDING A SPECIALTY PHARMA COMPANY PHOTOCURE ASA BUILDING A SPECIALTY PHARMA COMPANY RESULTS OF THE FIRST QUARTER 2013 25 April 2013 Kjetil Hestdal, MD, President & CEO Erik Dahl, CFO DISCLAIMER The information included in this Presentation

More information

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable

More information

QSC AG. Company Presentation. Preliminary Results 2013 / Outlook for 2014 Cologne, February 26, 2014

QSC AG. Company Presentation. Preliminary Results 2013 / Outlook for 2014 Cologne, February 26, 2014 QSC AG Company Presentation Preliminary Results 2013 / Outlook for 2014 Cologne, February 26, 2014 AGENDA 1. Strategic Development 2013 2. Financial Development 2013 3. Outlook for 2014 4. Questions &

More information

Delivering superior customer experiences and stable returns. Gjensidige Insurance Group July 2015

Delivering superior customer experiences and stable returns. Gjensidige Insurance Group July 2015 Delivering superior customer experiences and stable returns Gjensidige Insurance Group July 2015 Attractive value proposition Proven track-record Strong position in attractive market place Scalable hard-to-copy

More information

Conditional Regulatory Clearance of the acquisition of E-Plus

Conditional Regulatory Clearance of the acquisition of E-Plus Creating a Leading Digital Telco Conditional Regulatory Clearance of the acquisition of E-Plus July 2014 Disclaimer This document contains statements that constitute forward-looking statements and expectations

More information

Proactive Investors February 13, 2013. Enhancing lives and improving drugs

Proactive Investors February 13, 2013. Enhancing lives and improving drugs Proactive Investors February 13, 2013 Enhancing lives and improving drugs Disclaimer The information contained in this presentation and to be communicated during the management presentation based upon

More information

Prospectus. Nordic Nanovector AS

Prospectus. Nordic Nanovector AS Prospectus Nordic Nanovector AS (A private limited company incorporated under the laws of Norway) Offering of up to 2,000,000 Subsequent Offering Shares with Subscription Rights for Eligible Shareholders

More information

OPKO Health to Acquire Bio-Reference Laboratories

OPKO Health to Acquire Bio-Reference Laboratories OPKO Health to Acquire Bio-Reference Laboratories - Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy - Acquisition

More information

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

ING (US) ISSUANCE LLC REGISTRATION DOCUMENT

ING (US) ISSUANCE LLC REGISTRATION DOCUMENT Dated 15 May 2009 ING (US) ISSUANCE LLC REGISTRATION DOCUMENT Table of Contents Page INTRODUCTION... 1 DOCUMENTS INCORPORATED BY REFERENCE... 3 RISK FACTORS... 4 DESCRIPTION OF ING (US) ISSUANCE LLC....

More information

TERMS AND CONDITIONS OF USE

TERMS AND CONDITIONS OF USE TERMS AND CONDITIONS OF USE PLEASE READ THESE TERMS AND CONDITIONS OF USE CAREFULLY. THESE TERMS AND CONDITIONS OF USE MAY HAVE CHANGED SINCE YOUR LAST VISIT TO THIS WEB SITE. BY USING THIS WEB SITE, YOU

More information

Technip successfully places a «tap issue» of synthetic bonds

Technip successfully places a «tap issue» of synthetic bonds Paris, March 3, 2016 This press release does not constitute an offer of securities in the United States of America, Australia, Canada, Japan or South Africa or in any country where such issue of the Bonds

More information

Capio intends to be listed on the Nasdaq Stockholm Stock Exchange

Capio intends to be listed on the Nasdaq Stockholm Stock Exchange NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR PUBLICATION IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SINGAPORE

More information

Company announcement. Early close of offering of shares in DONG Energy. No. 18/2016

Company announcement. Early close of offering of shares in DONG Energy. No. 18/2016 Company announcement No. 18/2016 NOT FOR RELEASE OR DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN This announcement does

More information

SMA Solar Technology AG Analyst / Investor Presentation Quarterly Financial Report January to September 2008

SMA Solar Technology AG Analyst / Investor Presentation Quarterly Financial Report January to September 2008 SMA Solar Technology AG Analyst / Investor Presentation Quarterly Financial Report January to September 2008 November 14, 2008 2 Disclaimer IMPORTANT LEGAL NOTICE This presentation does not constitute

More information

Global Investments Limited. FY2014 Financial Results

Global Investments Limited. FY2014 Financial Results Global Investments Limited FY2014 Financial Results DISCLAIMER Information contained in this presentation is intended solely for your personal reference and is strictly confidential. Such information is

More information

Thule Group announces its intention to launch an initial public offering and listing on Nasdaq Stockholm

Thule Group announces its intention to launch an initial public offering and listing on Nasdaq Stockholm Malmö, 4 November, 2014 Thule Group announces its intention to launch an initial public offering and listing on Nasdaq Stockholm Thule Group AB (publ) ( Thule Group or the Company ) today announces its

More information

Geoff Miller CEO. GLI Finance. February 2014

Geoff Miller CEO. GLI Finance. February 2014 Geoff Miller CEO GLI Finance February 2014 1 Disclaimer IMPORTANT NOTICE These presentation materials (the "Presentation Materials") are being solely issued to and directed at persons who are qualified

More information

Cautionary Statement

Cautionary Statement Cautionary Statement The following document contains certain forward-looking statements and forward-looking information, which is based on current expectations, estimates, projections, assumptions and

More information

Magda Salarich Head of Santander Consumer Finance

Magda Salarich Head of Santander Consumer Finance Magda Salarich Head of Santander Consumer Finance Santander Consumer Finance S.A. ( Santander Consumer Finance ) and Banco Santander, S.A. ("Santander") both caution that this presentation contains forward-looking

More information

DNO ASA Corporate Presentation and Update

DNO ASA Corporate Presentation and Update DNO ASA Corporate Presentation and Update Haakon Sandborg, CFO Swedbank Nordic Energy Summit 19 March 2015 Oslo, Norway DNO at a glance Norwegian oil and gas operator focused on the Middle East and North

More information

AGM Presentation 27 November 2015

AGM Presentation 27 November 2015 AGM Presentation 27 November 2015 Agenda Overview Segments Services Consumer Lending Business Lending Financial results 2015 5 Year Strategic Plan 2016 to 2020 July to October 2015 2 Overview Overview

More information

2018-04 SEK ING Sprinter Sverige ING Bank NV (NL) 20 Units Outperformance Bonus Certificates linked to OMX due 2018-04

2018-04 SEK ING Sprinter Sverige ING Bank NV (NL) 20 Units Outperformance Bonus Certificates linked to OMX due 2018-04 2018-04 SEK ING Sprinter Sverige ING Bank NV (NL) 20 Units Outperformance Bonus Certificates linked to OMX due 2018-04 Product Description This 5YR SEK Outperformance Bonus Certificate is linked to the

More information

YIT Analyst lunch, December 2014 Co-operation projects as part of YIT s strategy

YIT Analyst lunch, December 2014 Co-operation projects as part of YIT s strategy Novo Orlovsky St. Petersburg, Russia YIT Analyst lunch, December 2014 Co-operation projects as part of YIT s strategy Kari Kauniskangas, President and CEO Contents 1 Co-operation projects, part of the

More information

Introducing SIR/GVV: the new Belgian REIT status

Introducing SIR/GVV: the new Belgian REIT status Introducing SIR/GVV: the new Belgian REIT status July 2014 1 Disclaimer This presentation (the Presentation) has been prepared by members of the working group (the Company) in connection with the adoption

More information

Gjensidige Pensjonsforsikring AS (GPF) Investor presentation. June 2016

Gjensidige Pensjonsforsikring AS (GPF) Investor presentation. June 2016 Gjensidige Pensjonsforsikring AS (GPF) Investor presentation June 2016 Disclaimer This presentation and the information contained herein have been prepared by and is the sole responsibility of Gjensidige

More information

Gruppo MutuiOnline First Half 2011 Results. 11 th August 2011

Gruppo MutuiOnline First Half 2011 Results. 11 th August 2011 Gruppo MutuiOnline First Half 211 Results 11 th August 211 Disclaimer Certain statements contained herein are statements of future expectations and other forward-looking statements. These expectations

More information

Tungsten Corporation PLC. Successful placing to raise 160 million significantly over subscribed. Admission to Trading on AIM

Tungsten Corporation PLC. Successful placing to raise 160 million significantly over subscribed. Admission to Trading on AIM NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN NOR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT

More information